Skip to main content
. 2008 May 23;4(5):e1000074. doi: 10.1371/journal.ppat.1000074

Figure 3. TRIMCyp is destabilized in cells challenged with HIV-1.

Figure 3

(A) 293T cells expressing the myc-His6 tagged TRIMCyp were pretreated for 1 hour with cycloheximide. Cells were then challenged with HIV-1(VSV) and either ethanol carrier (HIV-1) or CsA (HIV-1+CsA), or with media alone (Mock). All stocks contained cycloheximide. (B) Quantitation of TRIMCyp levels as described in the legend to Figure 1B. Data in this figure are from one of two independent experiments. (C) 293T cells expressing either myc-His6 tagged TRIMCyp or HA-tagged TRIM5αrh were pretreated for 1 hour with cycloheximide. Cells were then challenged for 5 hours with stock solutions of VSV-G pseudotyped HIV-GFP (WT), VSV-G pseudotyped HIV-GFP with the G89V capsid mutation (G89V), or medium alone (M). (D) Quantitation of TRIMCyp and TRIM5α levels as described in legend to Figure 1B. Data in (D) are expressed as the mean values of four determinations from two experiments, with error bars representing one standard deviation.